AMPH Amphastar Pharmaceuticals Inc

Price (delayed)

$31.78

Market cap

$1.55B

P/E Ratio

18.8

Dividend/share

N/A

EPS

$1.69

Enterprise value

$1.48B

Amphastar is a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin active ...

Highlights
The stock's P/E is 52% less than its last 4 quarters average of 39.0
Amphastar Pharmaceuticals's quick ratio has increased by 49% YoY and by 10% QoQ
AMPH's debt has surged by 63% year-on-year

Key stats

What are the main financial stats of AMPH
Market
Shares outstanding
48.83M
Market cap
$1.55B
Enterprise value
$1.48B
Valuations
Price to earnings (P/E)
18.8
Price to book (P/B)
3.19
Price to sales (P/S)
3.36
EV/EBIT
14
EV/EBITDA
11.3
EV/Sales
3.26
Earnings
Revenue
$455.12M
EBIT
$106.02M
EBITDA
$131.37M
Free cash flow
$99.96M
Per share
EPS
$1.69
Free cash flow per share
$2.08
Book value per share
$9.96
Revenue per share
$9.45
TBVPS
$14.08
Balance sheet
Total assets
$716.24M
Total liabilities
$236.71M
Debt
$105.28M
Equity
$479.53M
Working capital
$250.05M
Liquidity
Debt to equity
0.22
Current ratio
3.19
Quick ratio
2.3
Net debt/EBITDA
-0.51
Margins
EBITDA margin
28.9%
Gross margin
46.3%
Net margin
17.9%
Operating margin
17.8%
Efficiency
Return on assets
12%
Return on equity
18.3%
Return on invested capital
21.6%
Return on capital employed
17.6%
Return on sales
23.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AMPH stock price

How has the Amphastar Pharmaceuticals stock price performed over time
Intraday
-2.93%
1 week
0.82%
1 month
-6.36%
1 year
52.2%
YTD
36.45%
QTD
-11.48%

Financial performance

How have Amphastar Pharmaceuticals's revenue and profit performed over time
Revenue
$455.12M
Gross profit
$210.62M
Operating income
$81.2M
Net income
$81.33M
Gross margin
46.3%
Net margin
17.9%
The company's gross profit rose by 39% YoY and by 5% QoQ
The net income has grown by 31% from the previous quarter
AMPH's net margin is up by 26% since the previous quarter
Amphastar Pharmaceuticals's revenue has increased by 24% YoY and by 4% QoQ

Growth

What is Amphastar Pharmaceuticals's growth rate over time

Valuation

What is Amphastar Pharmaceuticals stock price valuation
P/E
18.8
P/B
3.19
P/S
3.36
EV/EBIT
14
EV/EBITDA
11.3
EV/Sales
3.26
The stock's P/E is 52% less than its last 4 quarters average of 39.0
The EPS has grown by 30% from the previous quarter
The price to book (P/B) is 28% higher than the 5-year quarterly average of 2.5 and 23% higher than the last 4 quarters average of 2.6
Amphastar Pharmaceuticals's equity has increased by 18% YoY and by 8% from the previous quarter
Amphastar Pharmaceuticals's revenue has increased by 24% YoY and by 4% QoQ
AMPH's price to sales (P/S) is 20% more than its last 4 quarters average of 2.8 and 12% more than its 5-year quarterly average of 3.0

Efficiency

How efficient is Amphastar Pharmaceuticals business performance
The company's return on assets rose by 28% QoQ
The ROE has grown by 25% from the previous quarter
The ROIC is up by 23% since the previous quarter
The ROS has grown by 22% from the previous quarter

Dividends

What is AMPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AMPH.

Financial health

How did Amphastar Pharmaceuticals financials performed over time
Amphastar Pharmaceuticals's quick ratio has increased by 49% YoY and by 10% QoQ
Amphastar Pharmaceuticals's current ratio has increased by 35% YoY and by 4.2% from the previous quarter
AMPH's debt is 78% smaller than its equity
AMPH's debt has surged by 63% year-on-year
Amphastar Pharmaceuticals's debt to equity has increased by 38% YoY but it has decreased by 4.3% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.